红杏加速器官网网址是多少

红杏加速器官网网址是多少

Male Apellis employee holding a horse saddle

Luis
Supply Chain at Apellis

红杏加速器官网网址是多少

Learn More
Folded page of a newspaper

红杏加速器官网网址是多少

红杏加速器官网网址是多少

Apellis Pharmaceuticals Reports Second Quarter 2023 Financial Results

红杏加速器官网网址是多少

Apellis Completes Enrollment in Two Phase 3 Studies of the Targeted C3 Therapy, Pegcetacoplan, in Patients with Geographic Atrophy (GA)

w加速器官网

Apellis Completes Enrollment in Phase 3 Study of Pegcetacoplan in Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Newsroom
w加速器安卓

@ApellisPharma

A man with a baby in a baby carrier

红杏加速器官网网址是多少

FOR PATIENTS
Erlenmeyer flask, which represents the pre-clinical and clinical studies sponsored by Apellis Pharmaceuticals

红杏加速器官网网址是多少

for paroxysmal nocturnal hemoglobinuria, geographic atrophy,
C3 glomerulopathy, and cold agglutinin disease.

PIPELINE
3 arrows of different lengths, which represents the development status of pre-clinical and clinical studies for C3 complement targeted therapies

红杏加速器官网网址是多少

are targeted C3 therapies. These include potential medicines for a broad range of serious diseases driven by uncontrolled or excessive activation of the complement system.

CLINICAL TRIALS

红杏加速器官网网址是多少

so that Alexander, who is living with C3 glomerulopathy, can take his pug for a hike

We challenge conventional thinking and always question if there's a better way.

Join Us
w加速器app

Patricia
Quality Assurance at Apellis

快连vp n官网是  七八九加速器  vpn 旋风  西柚加速器官方网站  旋风加速npv官网下载  快连vp安卓下载